Merck To Make Mighty Seasonal Gains?

Merck & Co., Inc., commonly known as Merck, is a multinational pharmaceutical company headquartered in Kenilworth, New Jersey, United States. Founded in 1891, Merck is one of the largest pharmaceutical companies globally, with operations in over 140 countries. Merck is known for its focus on research and development (R&D) in various therapeutic areas, including oncology, vaccines, infectious diseases, cardiovascular diseases, and diabetes. The company has a strong portfolio of prescription medicines, vaccines, biologic therapies, and animal health products.

Some of Merck’s notable products include Keytruda (pembrolizumab) for cancer immunotherapy, Gardasil for human papillomavirus (HPV) vaccination, and Januvia for type 2 diabetes treatment. Merck has also been involved in the development of vaccines, including the MMR (measles, mumps, and rubella) vaccine. According to statista Keytruda is not only Merck & Co.’s top product but also one of the best-selling drugs worldwide, generating some 25 billion U.S. dollars in revenue during 2023.Apart from its pharmaceutical business, Merck operates in animal health through its subsidiary, Merck Animal Health (known as MSD Animal Health outside the United States and Canada), providing veterinary products and services.

Merck has a very strong seasonal pattern coming up with an average return of nearly 5% and a winning trade percentage of 85% between April 01 and June 30th. The largest gain was nearly 15% in 2018 and the largest loss was 6.24% in 2012. Will Merck’s mighty seasonals play out again this year ?

Sign up here for thousands more seasonal insights waiting to be revealed!

The major trade risk here is that previous seasonal patterns do not play out again each and every year

Remember, don’t just trade it Seasonax It!